Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5161808 | 0.90 | HRH3 (0.37) | HRH3ALDH1A1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL5163233 | 0.79 | HRH3 (0.35) | HRH3KDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL5160185 | 0.79 | ACACB (0.36) | — | |
| SCHEMBL5160073 | 0.77 | HTT (0.39) | TSHRALDH1A1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL5161814 | 0.73 | AOC3 (0.39) | — | |
| SCHEMBL5418198 | 0.68 | HRH3 (0.37) | HRH3KDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL14371867 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL5158984 | 0.67 | HRH3 (0.36) | HRH3KDM4EGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL14146107 | 0.67 | CCNB2 (0.37) | TSHRKDM4EHSD17B10ALDH1A1CYP11B1 | |
| SCHEMBL14146033 | 0.67 | TSHR (0.39) | TSHRKDM4EHSD17B10ALDH1A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | HRH3 468/4885TSHR 1572/4885KDM4E 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.